After nearly a decade building a prescription-based video game platform to help children with attention deficit hyperactivity disorder (ADHD), Akili Interactive Labs’s CEO Eddie Martucci said the company is making plans to market its software to US-based health care providers and patients in the new year.
EndeavorRx became the first prescription-only game-based device to be cleared for marketing by the US FDA under the de novo clearance, the regulatory pathway for low- to moderate-risk devices. (
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?